利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

17 条记录 (耗时 0.021 秒)

    MUTANT VIRUSES AND USES THEREOF
    4.
    发明申请
    MUTANT VIRUSES AND USES THEREOF 失效
    突变病毒及其用途

    公开(公告)号：US20100272687A1

    公开(公告)日：2010-10-28

    申请号：US12750410

    申请日：2010-03-30

    申请人： John C. Bell ,  Brian D. Lichty ,  David F. Stojdl

    发明人： John C. Bell ,  Brian D. Lichty ,  David F. Stojdl

    IPC分类号： A61K35/76 ,  A61P35/00

    CPC分类号： C12N7/00 ,  A61K39/12 ,  A61K39/205 ,  A61K2039/522 ,  A61K2039/5254 ,  A61K2039/572 ,  A61K2039/585 ,  C07K14/005 ,  C07K2319/07 ,  C12N2760/20222 ,  C12N2760/20232 ,  C12N2760/20234 ,  C12N2760/20261

    摘要： The present invention provides mutant viruses with a decreased ability to block nuclear transport of mRNA or protein in an infected cell which are attenuated in vivo. The mutant viruses of the present invention may also be capable of triggering the anti-viral systems of normal host cells while remaining sensitive to the effects of these systems. The present invention further provides for the use of the mutant viruses in a range of applications including, but not limited to, as therapeutics for the treatment of cancer and infections, as vaccines and adjuvants, as viral vectors, and as oncolytic and cytolytic agents for the selective lysis of malignant or infected cells.

    摘要翻译： 本发明提供了在体内减毒的受感染细胞中阻断mRNA或蛋白质的核转运能力降低的突变病毒。 本发明的突变病毒还可能能够触发正常宿主细胞的抗病毒系统，同时对这些系统的作用保持敏感。 本发明还提供了在一系列应用中使用突变病毒，包括但不限于作为治疗癌症和感染的治疗剂，作为疫苗和佐剂，作为病毒载体，以及作为溶瘤和细胞溶解剂 选择性裂解恶性或感染细胞。

    Attenuation of negative stranded RNA viruses by rearrangement of genes and uses thereof
    6.
    发明授权
    Attenuation of negative stranded RNA viruses by rearrangement of genes and uses thereof 失效
    通过基因重排减少负链RNA病毒及其用途

    公开(公告)号：US6136585A

    公开(公告)日：2000-10-24

    申请号：US71606

    申请日：1998-05-01

    申请人： L. Andrew Ball ,  Gail W. Wertz

    发明人： L. Andrew Ball ,  Gail W. Wertz

    IPC分类号： C12N15/09 ,  A61K39/00 ,  A61K39/12 ,  A61K39/155 ,  A61K39/205 ,  C12N7/04 ,  C12N15/86

    CPC分类号： C12N7/00 ,  A61K39/12 ,  A61K39/205 ,  C12N15/86 ,  A61K2039/5254 ,  A61K2039/543 ,  C12N2760/20234 ,  C12N2760/20243 ,  C12N2760/20261

    摘要： Provided is a method of attenuating a virus of the order Mononegavirales, comprising the step of: rearranging said virus' gene order by moving a gene essential for RNA replication away from its wild-type 3' promoter proximal position site, wherein said gene is an essential limiting factor for genome replication and is placed in the next to last position in the gene order. Also provided is a method of making an attenuated virus useful for a vaccine, comprising the steps of: rearranging said virus' gene order by moving a gene essential for RNA replication away from its wild-type 3' promoter proximal position site, wherein a gene which is a n essential limiting factor for genome replication is placed in the next to last position in the gene order; and placing a gene coding for an immune response inducing antigen in the position closest to the 3' end of the gene order. Also provided is a method of attenuating a virus of the order Mononegavirales, comprising the step of: rearranging said virus' gene order.

    摘要翻译： 本发明提供一种减毒单宁病毒病毒的方法，包括以下步骤：通过将RNA复制所必需的基因从其野生型3'启动子近端位点移动而重新排列所述病毒基因顺序，其中所述基因是 基因组复制的基本限制因素，并被置于下一个基因顺序的最后位置。 还提供了制备可用于疫苗的减毒病毒的方法，包括以下步骤：通过将RNA复制必需的基因移动离开其野生型3'启动子近端位点来重排所述病毒的基因顺序，其中基因 这是基因组复制的基本限制因素放在基因顺序的最后一个位置; 并将编码免疫应答诱导抗原的基因置于最靠近基因顺序3'末端的位置。 还提供了减毒单宁病毒的病毒的方法，其包括以下步骤：重新排列所述病毒的基因顺序。

    COMPOSITIONS AND METHODS FOR TREATING CANCER WITH ATTENUATED ONCOLYTIC VIRUSES
    7.
    发明申请
    COMPOSITIONS AND METHODS FOR TREATING CANCER WITH ATTENUATED ONCOLYTIC VIRUSES 审中-公开
    用于治疗患有衰老的光感病毒的癌症的组合物和方法

    公开(公告)号：US20120315248A1

    公开(公告)日：2012-12-13

    申请号：US13464692

    申请日：2012-05-04

    申请人： Anthony N. van den Pol ,  Guido Wollmann

    发明人： Anthony N. van den Pol ,  Guido Wollmann

    IPC分类号： A61K35/76 ,  A61P35/00

    CPC分类号： A61K38/21 ,  A61K35/766 ,  C12N7/00 ,  C12N2760/20232 ,  C12N2760/20261 ,  A61K2300/00

    摘要： Compositions including attenuated oncolytic viruses and methods of their use for the treatment of cancer are disclosed. Some attenuated virus exhibit potential as tumor therapies by exhibiting characteristics such as high selectivity, infectivity, cytotoxicity, or replication index for tumor cells, and/or low infectivity, cytotoxicity, or replication index for normal cells. In preferred embodiments, the ratio of replication of virus in normal cells:tumor cells is about 1:100 or greater. Preferred viruses have two or more mechanisms of attenuation including insertion of a transgene such as GFP or an interferon, preferably at position 1 of the viral genome. The compositions can be administered to subjects having tumors, in an effective amount to delay or inhibit the growth of a tumor, reduce the growth or size of the tumor, and/or inhibit or reduce metastasis of the tumor. Methods for manufacturing viruses and methods of testing their oncolytic potential are also disclosed.

    摘要翻译： 公开了包括减毒的溶瘤病毒及其用于治疗癌症的方法的组合物。 一些减毒病毒通过展现诸如肿瘤细胞的高选择性，感染性，细胞毒性或复制指数等特征，和/或正常细胞的低感染性，细胞毒性或复制指数，来表现出作为肿瘤治疗的潜力。 在优选的实施方案中，病毒在正常细胞中的复制比例：肿瘤细胞约为1:100或更大。 优选的病毒具有两种或更多种衰减机制，包括插入转基因例如GFP或干扰素，优选在病毒基因组的位置1。 组合物可以以有效量施用于具有肿瘤的受试者，以延缓或抑制肿瘤的生长，减少肿瘤的生长或大小，和/或抑制或减少肿瘤的转移。 还公开了制造病毒的方法和测试其溶瘤潜力的方法。